Literature DB >> 10492286

Use of aerosolized antibiotics in patients with cystic fibrosis.

P W Campbell, L Saiman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10492286     DOI： 10.1378/chest.116.3.775

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  9 in total

1.  Microparticles for inhalational delivery of antipseudomonal antibiotics.

Authors:  Michael D Tsifansky; Yoon Yeo; Oleg V Evgenov; Evangelia Bellas; John Benjamin; Daniel S Kohane
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

Review 2.  Aerosol therapy for obstructive lung diseases: device selection and practice management issues.

Authors:  Michael W Sims
Journal:  Chest       Date:  2011-09       Impact factor: 9.410

3.  Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis.

Authors:  L Saiman; S Tabibi; T D Starner; P San Gabriel; P L Winokur; H P Jia; P B McCray; B F Tack
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

4.  In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species.

Authors:  John J LiPuma; Sivaprakash Rathinavelu; Bridget K Foster; Jordan C Keoleian; Paul E Makidon; Linda M Kalikin; James R Baker
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

5.  Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency.

Authors:  Chiara Parlati; Paolo Colombo; Francesca Buttini; Paul M Young; Handoko Adi; Alaina J Ammit; Daniela Traini
Journal:  Pharm Res       Date:  2009-01-31       Impact factor: 4.200

6.  Aerosolized Delivery of Antifungal Agents.

Authors:  Jennifer Le; Daryl S Schiller
Journal:  Curr Fungal Infect Rep       Date:  2010-04-13

7.  Comparative efficacy of two doses of nebulized colistimethate in the eradication of Pseudomonas aeruginosa in children with cystic fibrosis.

Authors:  Marie-Sophie Brochet; Anne-Cathrine McDuff; Jean-François Bussières; Elaine Caron; Geneviève Fortin; Denis Lebel; Jacques-Edouard Marcotte
Journal:  Can Respir J       Date:  2007 Nov-Dec       Impact factor: 2.409

8.  Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.

Authors:  Gianluigi Poli; Daniela Acerbi; Roberto Pennini; Annamaria Soliani Raschini; Mario Ermanno Corrado; Hans Georg Eichler; Irmgard Eichler
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

9.  Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis.

Authors:  Pablo San Gabriel; Juyan Zhou; Setareh Tabibi; Yunhua Chen; Marco Trauzzi; Lisa Saiman
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.